# Influenza Vaccination Strategy for Patients With Hematologic Malignancy

> **NCT07485855** · PHASE3 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Hematologic Neoplasms
- Influenza
- Immunogenicity

## Interventions

- **BIOLOGICAL:** High-dose trivalent inactivated influenza vaccine (HD-IIV3)
- **BIOLOGICAL:** MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4)
- **BIOLOGICAL:** Standard-dose trivalent inactivated influenza vaccine (SD-IIV3)

## Key facts

- **NCT ID:** NCT07485855
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07485855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07485855, "Influenza Vaccination Strategy for Patients With Hematologic Malignancy". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07485855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*